Progress and challenges associated with the development of ricin toxin subunit vaccines

References

• Reisler RB, Smith LA. The need for continued development of ricin countermeasures. Adv Prev Med. 2012;2012:149737.
   PubMedGoogle Scholar
• Wolfe DN, Florence W, Bryant P. Current biodefense vaccine programs and challenges. Human Vaccines & Immunotherapeutics. 1591-1597;9(7):2013.
   Google Scholar
• Approval of biological products when human efficacy studies are not ethical or feasible. Available from: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=601&showFR=1&subpartNode=21:7.0.1.1.2.8)
   Google Scholar
• Griffiths GD. Understanding ricin from a defensive viewpoint. Toxins (Basel). 2011;3(11):1373–1392.
   PubMed Web of Science ®Google Scholar
• Worbs S, Kohler K, Pauly D, et al. Ricinus communis intoxications in human and veterinary medicine-a summary of real cases. Toxins (Basel). 2011;3(10):1332–1372.
   PubMed Web of Science ®Google Scholar
• Spooner RA, Lord JM. How ricin and shiga toxin reach the cytosol of target cells: retrotranslocation from the endoplasmic reticulum. Curr Top Microbiol Immunol. 2012;357:19–40.
   PubMed Web of Science ®Google Scholar
• Tesh VL. The induction of apoptosis by Shiga toxins and ricin. Curr Top Microbiol Immunol. 2012;357:137–178.
   PubMed Web of Science ®Google Scholar
• Ne T, Xp L. Interaction of ricin and Shiga toxins with ribosomes. Curr Top Microbiol Immunol. 2012;357:1–18.
   PubMed Web of Science ®Google Scholar
• Roy CJ, Song K, Sivasubramani SK, et al. Animal models of ricin toxicosis. Curr Top Microbiol Immunol. 2012;357:243–257.
   Web of Science ®Google Scholar
• O’Hara JM, Yermakova A, Mantis NJ. Immunity to ricin: fundamental insights into toxin-antibody interactions. Curr Top Microbiol Immunol. 2012;357:209–241.
   PubMed Web of Science ®Google Scholar
• Je S, Es V. Ricin vaccine development. Curr Top Microbiol Immunol. 2012;357:259–272.
   PubMed Web of Science ®Google Scholar
• Pg W, Jd R, Nj M. Small-molecule inhibitors of ricin and Shiga toxins. Curr Top Microbiol Immunol. 2012;357:179–207.
   PubMed Web of Science ®Google Scholar
• Mantis NJ. Ricin Toxin. In: Liu D, editor. Manual of security sensitive microbes and toxins. Boca Raton (FL): CRC Press; 2014, p. 1024.
   Google Scholar
• Schrot J, Weng A, Melzig MF. Ribosome-inactivating and related proteins. Toxins (Basel). 2015;7(5):1556–1615.
   PubMed Web of Science ®Google Scholar
• Final report on the safety assessment of ricinus communis (castor) seed oil, hydrogenated castor oil, glyceryl ricinoleate, glyceryl ricinoleate SE, ricinoleic acid, potassium ricinoleate, sodium ricinoleate, zinc ricinoleate, cetyl ricinoleate, ethyl ricinoleate, glycol ricinoleate, isopropyl ricinoleate, methyl ricinoleate, and octyldodecyl ricinoleate. Int J Toxicol. 2007;26 Suppl 3:31–77.
   PubMed Web of Science ®Google Scholar
• Da Silva Nde L, Maciel MR, Batistella CB, et al. Optimization of biodiesel production from castor oil. Appl Biochem Biotechnol. 2006;129-132:405–414.
   PubMedGoogle Scholar
• Katzin BJ, Collins EJ, Robertus JD. Structure of ricin A-chain at 2.5 A. Proteins. 1991;10(3):251–259.
   PubMed Web of Science ®Google Scholar
• Montfort W, Villafranca JE, Monzingo AF, et al. The three-dimensional structure of ricin at 2.8 A. J Biol Chem. 1987;262(11):5398–5403.
   PubMed Web of Science ®Google Scholar
• Robertus JD, Piatak M, Ferris R, et al. Crystallization of ricin A chain obtained from a cloned gene expressed in Escherichia coli. J Biol Chemistry. 1987;262(1):19–20.
   PubMed Web of Science ®Google Scholar
• Rutenber E, Katzin BJ, Ernst S, et al. Crystallographic refinement of ricin to 2.5 A. Proteins. 1991;10(3):240–250.
   PubMed Web of Science ®Google Scholar
• Olsnes S, Fernandez-Puentes C, Carrasco L, et al. Ribosome inactivation by the toxic lectins abrin and ricin. Kinetics of the enzymic activity of the toxin A-chains. Eur J Biochem. 1975;60(1):281–288.
   PubMedGoogle Scholar
• Endo Y, Mitsui K, Motizuki M, et al. The mechanism of action of ricin and related toxins on eukaryotic ribosomes. J Biol Chem. 1987;262:5908–5912.
   PubMed Web of Science ®Google Scholar
• Endo Y, Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J Biol Chem. 1987;262(17):8128–8130.
   PubMed Web of Science ®Google Scholar
• Monzingo AF, Robertus JD. X-ray analysis of substrate analogs in the ricin A-chain active site. J Mol Biol. 1136-1145;227(4):1992.
   Google Scholar
• Rutenber E, Robertus JD. Structure of ricin B-chain at 2.5 A resolution. Proteins. 1991;10(3):260–269.
   PubMed Web of Science ®Google Scholar
• Smallshaw JE, Firan A, Fulmer JR, et al. A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine. 2002;20(27–28):3422–3427.
   PubMed Web of Science ®Google Scholar
• Weston SA, Tucker AD, Thatcher DR, et al. X-ray structure of recombinant ricin A-chain at 1.8 A resolution. J Mol Biol. 1994;244(4):410–422.
   PubMed Web of Science ®Google Scholar
• Lord JM, Roberts LM, Robertus JD. Ricin: structure, mode of action, and some current applications. Faseb J. 1994;8(2):201–208.
   PubMed Web of Science ®Google Scholar
• Rutenber E, Ready M, Robertus JD. Structure and evolution of ricin B chain. Nature. 1987;326(6113):624–626.
   PubMed Web of Science ®Google Scholar
• Swimmer C, Lehar SM, McCafferty J, et al. Phage display of ricin B chain and its single binding domains: system for screening galactose-binding mutants. ProcNatlAcad Sci U S. 1992;89(9):3756–3760.
   PubMed Web of Science ®Google Scholar
• Baenziger JU, Fiete D. Structural determinants of Ricinus communis agglutinin and toxin specificity for oligosaccharides. J. Biol. Chem. 9795-9799;254(19):1979.
   Google Scholar
• Newton DL, Wales R, Richardson PT, et al. Cell surface and intracellular functions for ricin galactose binding. J Biol Chem. 1992;267(17):11917–11922.
   PubMed Web of Science ®Google Scholar
• Zentz C, Frenoy JP, Bourrillon R. Binding of galactose and lactose to ricin. Equilibrium studies. Biochim Biophys Acta. 1978;536(1):18–26.
   PubMed Web of Science ®Google Scholar
• Sphyris N, Lord JM, Wales R, et al. Mutational analysis of the Ricinus lectin B-chains. Galactose-binding ability of the 2 gamma subdomain of Ricinus communis agglutinin B-chain. J Biol Chem. 1995;270(35):20292–20297.
   PubMed Web of Science ®Google Scholar
• Sandvig K, Skotland T, Van Deurs B, et al. Retrograde transport of protein toxins through the Golgi apparatus. Histochem Cell Biol. 2013;140:317–326.
   PubMed Web of Science ®Google Scholar
• Spooner RA, Lord JM. Ricin trafficking in cells. Toxins (Basel). 2015;7(1):49–65.
   PubMed Web of Science ®Google Scholar
• Slominska-Wojewodzka M, Gregers TF, Walchli S, et al. EDEM is involved in retrotranslocation of ricin from the endoplasmic reticulum to the cytosol. Mol Biol Cell. 2006;17(4):1664–1675.
   PubMed Web of Science ®Google Scholar
• Sokolowska I, Walchli S, Wegrzyn G, et al. A single point mutation in ricin A-chain increases toxin degradation and inhibits EDEM1-dependent ER retrotranslocation. Biochem J. 2011;436(2):371–385.
   PubMed Web of Science ®Google Scholar
• Spooner RA, Watson PD, Marsden CJ, et al. Protein disulphide-isomerase reduces ricin to its A and B chains in the endoplasmic reticulum. Biochem J. 2004;383(Pt 2):285–293.
   PubMed Web of Science ®Google Scholar
• Argent RH, Parrott AM, Day PJ, et al. Ribosome-mediated folding of partially unfolded ricin A-chain. J Biol Chem. 2000;275(13):9263–9269.
   PubMed Web of Science ®Google Scholar
• Li S, Spooner RA, Allen SC, et al. Folding-competent and folding-defective forms of ricin A chain have different fates after retrotranslocation from the endoplasmic reticulum. Mol Biol Cell. 2010;21(15):2543–2554.
   PubMed Web of Science ®Google Scholar
• Spooner RA, Hart PJ, Cook JP, et al. Cytosolic chaperones influence the fate of a toxin dislocated from the endoplasmic reticulum. Proc Natl Acad Sci U S A. 2008;105(45):17408–17413.
   PubMed Web of Science ®Google Scholar
• Gluck A, Endo Y, Wool IG. The ribosomal RNA identity elements for ricin and for alpha-sarcin: mutations in the putative CG pair that closes a GAGA tetraloop. Nucleic Acids Res. 1994;22(3):321–324.
   PubMed Web of Science ®Google Scholar
• Iordanov MS, Pribnow D, Magun JL, et al. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol. 1997;17(6):3373–3381.
   PubMed Web of Science ®Google Scholar
• Jandhyala DM, Thorpe CM, Magun B. Ricin and Shiga toxins: effects on host cell signal transduction. Curr Top Microbiol Immunol. 2012;357:41–65.
   PubMed Web of Science ®Google Scholar
• Pincus SH, Bhaskaran M, Brey RN 3rd, et al. Clinical and pathological findings associated with aerosol exposure of macaques to ricin toxin. Toxins (Basel). 2015;7(6):2121–2133.
   PubMed Web of Science ®Google Scholar
• Roy CJ, Brey RN, Mantis NJ, et al. Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection. Proc Natl Acad Sci U S A. 2015;112(12):3782–3787.
   PubMed Web of Science ®Google Scholar
• Smallshaw JE, Richardson JA, Vitetta ES. RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine. 2007;25(42):7459–7469.
   PubMed Web of Science ®Google Scholar
• Bhaskaran M, Didier PJ, Sivasubramani SK, et al. Pathology of lethal and sublethal doses of aerosolized ricin in rhesus macaques. Toxicol Pathol. 2013;42(3):573–581.
   PubMed Web of Science ®Google Scholar
• Brown RF, White DE. Ultrastructure of rat lung following inhalation of ricin aerosol. IntJ Exp Path. 1997;78(4):267–276.
   PubMed Web of Science ®Google Scholar
• Wilhelmsen CL, Pitt ML. Lesions of acute inhaled lethal ricin intoxication in rhesus monkeys. Vet Pathology. 1996;33(3):296–302.
   PubMed Web of Science ®Google Scholar
• Smallshaw JE, Ghetie V, Rizo J, et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol. 2003;21(4):387–391.
   PubMed Web of Science ®Google Scholar
• Legler PM, Brey RN, Smallshaw JE, et al. Structure of RiVax: a recombinant ricin vaccine. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 9):826–830.
   PubMedGoogle Scholar
• Mlsna D, Monzingo AF, Katzin BJ, et al. Structure of recombinant ricin A chain at 2.3 A. Protein Sci. 1993;2(3):429–435.
   PubMed Web of Science ®Google Scholar
• Compton JR, Legler PM, Clingan BV, et al. Introduction of a disulfide bond leads to stabilization and crystallization of a ricin immunogen. Proteins. 2011;79(4):1048–1060.
   PubMed Web of Science ®Google Scholar
• Rudolph MJ, Vance DJ, Cheung J, et al. Crystal structures of ricin toxin’s enzymatic subunit (RTA) in complex with neutralizing and non-neutralizing single-chain antibodies. J Mol Biol. 2014;426(17):3057–3068.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Dai J, Zhang T, et al. Structural insights into the neutralization mechanism of monoclonal antibody 6C2 against ricin. J Biol Chem. 2013;288(35):25165–25172.
   PubMed Web of Science ®Google Scholar
• Carra JH, Wannemacher RW, Tammariello RF, et al. Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. Vaccine. 2007;25(21):4149–4158.
   PubMed Web of Science ®Google Scholar
• McHugh CA, Tammariello RF, Millard CB, et al. Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein Sci. 2004;13(10):2736–2743.
   PubMed Web of Science ®Google Scholar
• Olson MA, Carra JH, Roxas-Duncan V, et al. Finding a new vaccine in the ricin protein fold. Protein Engineering, Design & Selection: PEDS. 2004;17(4):391–397.
   PubMed Web of Science ®Google Scholar
• O’Hara JM, Kasten-Jolly JC, Reynolds CE, et al. Localization of non-linear neutralizing B cell epitopes on ricin toxin’s enzymatic subunit (RTA). Immunol Lett. 2014;158(1–2):7–13.
   PubMed Web of Science ®Google Scholar
• Marconescu PS, Smallshaw JE, Pop LM, et al. Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. Vaccine. 2010;28(32):5315–5322.
   PubMed Web of Science ®Google Scholar
• Smallshaw JE, Richardson JA, Pincus S, et al. Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine. 2005;23(39):4775–4784.
   PubMed Web of Science ®Google Scholar
• McLain DE, Horn TL, Detrisac CJ, et al. Progress in biological threat agent vaccine development: a repeat-dose toxicity study of a recombinant ricin toxin A-chain (rRTA) 1-33/44-198 vaccine (RVEc) in male and female New Zealand white rabbits. Int J Toxicol. 2011;30:143–152.
   PubMed Web of Science ®Google Scholar
• McLain DE, Lewis BS, Chapman JL, et al. Protective effect of two recombinant ricin subunit vaccines in the New Zealand white rabbit subjected to a lethal aerosolized ricin challenge: survival, immunological response and histopathological findings. Toxicol Sci. 2011;126(1):72–83.
   PubMed Web of Science ®Google Scholar
• O’Hara JM, Brey RN 3rd, Mantis NJ. Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice. Clin Vaccine Immunol. 2013;20(6):789–794.
   PubMed Web of Science ®Google Scholar
• Vance DJ, Greene CJ, Rong Y, et al. Comparative adjuvant effects of type II heat-labile enterotoxins in combination with two different candidate ricin toxin vaccine antigens. Clin Vaccine Immunol. 2015;22(12):1285–1293.
   PubMed Web of Science ®Google Scholar
• Pittman PR, Reisler RB, Lindsey CY, et al. Safety and immunogenicity of ricin vaccine, RVEc, in a phase 1 clinical trial. Vaccine. 2015;33(51):7299–7306.
   PubMed Web of Science ®Google Scholar
• Vitetta ES, Smallshaw JE, Schindler J. Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine. Clin Vaccine Immunol. 2012;19(10):1697–1699.
   PubMed Web of Science ®Google Scholar
• Lindsey CY, Brown JE, Torabazar NR, et al. EL4 cell-based colorimetric toxin neutralization activity assays for determination of neutralizing anti-ricin antibodies. J AOAC Int. 2013;96(1):147–154.
   PubMed Web of Science ®Google Scholar
• Vitetta ES, Smallshaw JE, Coleman E, et al. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci U S A. 2006;103(7):2268–2273.
   PubMed Web of Science ®Google Scholar
• Vance DJ, Rong Y, Brey RN 3rd, et al. Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice. Vaccine. 2015;33(3):417–421.
   PubMed Web of Science ®Google Scholar
• Rath T, Baker K, Pyzik M, et al. Regulation of immune responses by the neonatal fc receptor and its therapeutic implications. Front Immunol. 2014;5:664.
   PubMed Web of Science ®Google Scholar
• Boles JW, Pitt ML, LeClaire RD, et al. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol. 2003;108(1):51–59.
   PubMed Web of Science ®Google Scholar
• Hassett KJ, Cousins MC, Rabia LA, et al. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization. Eur J Pharm Biopharm. 2013;85(2):279–286.
   PubMed Web of Science ®Google Scholar
• Piatak M, Lane JA, Laird W, et al. Expression of soluble and fully functional ricin A chain in Escherichia coli is temperature-sensitive. J Biol Chem. 1988;263(10):4837–4843.
   PubMed Web of Science ®Google Scholar
• Janosi L, Compton JR, Legler PM, et al. Disruption of the putative vascular leak peptide sequence in the stabilized ricin vaccine candidate RTA1-33/44-198. Toxins (Basel). 2013;5(2):224–248.
   PubMed Web of Science ®Google Scholar
• Alving CR, Peachman KK, Rao M, et al. Adjuvants for human vaccines. Curr Opin Immunol. 2012;24(3):310–315.
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.
   PubMed Web of Science ®Google Scholar
• Foged C, Rades T, Perrie Y, et al., eds. Subunit vaccine delivery. New York (NY): Springer-Verlag; 2015.
   Google Scholar
• Greene CJ, Chadwick CM, Mandell LM, et al. LT-IIb(T13I), a non-toxic type II heat-labile enterotoxin, augments the capacity of a ricin toxin subunit vaccine to evoke neutralizing antibodies and protective immunity. PLoS One. 2013;8(8):e69678.
   PubMed Web of Science ®Google Scholar
• Neal LM, O’Hara J, Brey RN 3rd, et al. A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin. Infect Immun. 2010;78(1):552–561.
   PubMed Web of Science ®Google Scholar
• O’Hara JM, Mantis NJ. Neutralizing monoclonal antibodies against ricin’s enzymatic subunit interfere with protein disulfide isomerase-mediated reduction of ricin holotoxin in vitro. J Immunol Methods. 2013;395(1–2):71–78.
   PubMed Web of Science ®Google Scholar
• Jm O, Lm N, Ea M, et al. Folding domains within the ricin toxin A subunit as targets of protective antibodies. Vaccine. 2010;28:7035–7046.
   PubMed Web of Science ®Google Scholar
• O’Hara JM, Whaley K, Pauly M, et al. Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit. Vaccine. 2012;30(7):1239–1243.
   PubMed Web of Science ®Google Scholar
• Sully EK, Whaley KJ, Bohorova N, et al. Chimeric plantibody passively protects mice against aerosolized ricin challenge. Clin Vaccine Immunol. 2014;21(5):777–782.
   PubMed Web of Science ®Google Scholar
• Pincus SH, Das A, Song K, et al. Role of Fc in antibody-mediated protection from ricin toxin. Toxins (Basel). 2014;6(5):1512–1525.
   PubMed Web of Science ®Google Scholar
• Prigent J, Panigai L, Lamourette P, et al. Neutralising antibodies against ricin toxin. PLoS One. 2011;6(5):e20166.
   PubMed Web of Science ®Google Scholar
• Yermakova A, Mantis NJ. Protective immunity to ricin toxin conferred by antibodies against the toxin’s binding subunit (RTB). Vaccine. 2011;29(45):7925–7935.
   PubMed Web of Science ®Google Scholar
• Yermakova A, Mantis NJ. Neutralizing activity and protective immunity to ricin toxin conferred by B subunit (RTB)-specific Fab fragments. Toxicon. 2013;72:29–34.
   PubMed Web of Science ®Google Scholar
• Yermakova A, Vance DJ, Mantis NJ. Sub-domains of ricin’s B subunit as targets of toxin neutralizing and non-neutralizing monoclonal antibodies. PLoS One. 2012;7(9):e44317.
   PubMed Web of Science ®Google Scholar
• Wahome PG, Mantis NJ. High-throughput, cell-based screens to identify small-molecule inhibitors of ricin toxin and related category B ribosome inactivating proteins (RIPs). Curr Protoc Toxicol. Chapter 2, Unit2 23. (2013).
   PubMedGoogle Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2008;47(3):401–409.
   PubMed Web of Science ®Google Scholar
• Abboud N, Chow SK, Saylor C, et al. A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization. J Exp Med. 2010;207(11):2395–2405.
   PubMed Web of Science ®Google Scholar
• Pohl MA, Rivera J, Nakouzi A, et al. Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays. Infect Immun. 2013;81(6):1880–1888.
   PubMed Web of Science ®Google Scholar
• Hu CC, Yin J, Chau D, et al. Active immunity induced by passive IgG post-exposure protection against ricin. Toxins (Basel). 2014;6(1):380–393.
   PubMed Web of Science ®Google Scholar
• Burbelo PD, Ching KH, Bush ER, et al. Antibody-profiling technologies for studying humoral responses to infectious agents. Expert Rev Vaccines. 2010;9(6):567–578.
   PubMed Web of Science ®Google Scholar
• Furman D, Davis MM. New approaches to understanding the immune response to vaccination and infection. Vaccine. 2015;33(40):5271–5281.
   PubMed Web of Science ®Google Scholar
• Nakaya HI, Hagan T, Duraisingham SS, et al. Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. Immunity. 2015;43(6):1186–1198.
   PubMed Web of Science ®Google Scholar
• Lemley PV, Amanatides P, Wright DC. Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma. 1994;13(5):417–421.
   PubMedGoogle Scholar
• Aboud-Pirak E, Hack D, Olson MA, et al. Identification of a neutralizing epitope on ricin A chain and application of its 3D stucture to design peptide vaccines that protect against ricin intoxication. In: 1993 medical defense bioscience review. Baltimore (MD): US Army Medical Research and Material Command; 1993
   Google Scholar
• Lebeda FJ, Olson MA. Prediction of a conserved, neutralizing epitope in ribosome-inactivating proteins. Int J Biol Macromol. 1999;24(1):19–26.
   PubMed Web of Science ®Google Scholar
• Vance DJ, Mantis NJ. Resolution of two overlapping neutralizing B cell epitopes within a solvent exposed, immunodominant alpha-helix in ricin toxin’s enzymatic subunit. Toxicon. 2012;60(5):874–877.
   PubMed Web of Science ®Google Scholar
• Vance DJ, Tremblay JM, Mantis NJ, et al. Stepwise engineering of heterodimeric single domain camelid VHH antibodies that passively protect mice from ricin toxin. J Biol Chem. 2013;288(51):36538–36547.
   PubMed Web of Science ®Google Scholar
• Castelletti D, Fracasso G, Righetti S, et al. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin’s lymphoma patients treated with an anti-CD25 immunotoxin. Clin Exp Immunol. 2004;136(2):365–372.
   PubMed Web of Science ®Google Scholar